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Perfluorooctanoic acid (PFOA) is an environmental contami-
nant that causes adverse developmental effects in laboratory
animals. To investigate the low-dose effects of PFOA on offspring,
timed-pregnant CD-1 mice were gavage dosed with PFOA for all
or half of gestation. In the full-gestation study, mice were
administered 0, 0.3, 1.0, and 3.0 mg PFOA/kg body weight
(BW)/day from gestation days (GD) 1–17. In the late-gestation
study, mice were administered 0, 0.01, 0.1, and 1.0 mg PFOA/kg
BW/day from GD 10–17. Exposure to PFOA significantly (p <
0.05) increased offspring relative liver weights in all treatment
groups in the full-gestation study and in the 1.0 mg PFOA/kg
group in the late-gestation study. In both studies, the offspring of
all PFOA-treated dams exhibited significantly stunted mammary
epithelial growth as assessed by developmental scoring. At
postnatal day 21, mammary glands from the 1.0 mg/kg GD 10–
17 group had significantly less longitudinal epithelial growth and
fewer terminal end buds compared with controls (p < 0.05).
Evaluation of internal dosimetry in offspring revealed that PFOA
concentrations remained elevated in liver and serum for up to 6
weeks and that brain concentrations were low and undetectable
after 4 weeks. These data indicate that PFOA-induced effects on
mammary tissue (1) occur at lower doses than effects on liver
weight in CD-1 mice, an observation that may be strain specific,
and (2) persist until 12 weeks of age following full-gestational
exposure. Due to the low-dose sensitivity of mammary glands to
PFOA in CD-1 mice, a no observable adverse effect level for
mammary developmental delays was not identified in these
studies.
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Perfluorooctanoic acid (PFOA) is a synthetic eight-carbon
perfluorinated compound that is commonly used in the
production of fluorotelomers due to its physicochemical
properties. PFOA has widespread industrial applications, is
persistent in the environment, and is also the final breakdown
product of several fluorotelomers (Wang et al., 2005). This
surfactant is ubiquitous in the environment and has been
detected in sera of animals and humans (Giesy and Kannan,
2002; Olsen et al., 2003). For these reasons, PFOA has become
a heavily studied environmental contaminant.
Humans are thought to be exposed to PFOA mainly through
ingestion of contaminated water or food products (Begley
et al., 2005; Björklund et al., 2009; Gulkowska et al., 2006)
and also through residues found in residential dust (Björklund
et al., 2009; Strynar and Lindstrom, 2008). PFOA is found in
cord blood, human, and rodent milk and, as such, can be passed
to developing offspring (Apelberg et al., 2007; Fenton et al.,
2009; Hinderliter et al., 2005; Völkel et al., 2008). The most
recent U.S. geometric mean serum PFOA concentration is 3.9
ng/ml (2003–2004, Calafat et al., 2007) according to
population-based biomonitoring studies; yet, in young children,
serum PFOA concentrations are slightly higher (6.1–7.6 ng/ml,
least square mean estimates, 2001–2002; Kato et al., 2009).
PFOA is a persistent compound as it is slowly eliminated from
the body, with an estimated half-life in adult humans of 3.8
years (Olsen et al., 2007). Due to the risk for developmental
exposure, its ubiquitous nature, and the presence of this
compound at relatively high levels in certain communities
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(Emmett et al., 2006), developmental exposure studies were
initiated in the United States and other countries to determine
potential adverse health effects of PFOA exposure (Apelberg
et al., 2007; C8 Science Panel, 2010; Fei et al., 2007, 2008;
Fromme et al., 2010; Hamm et al., 2009; Midasch et al., 2007;
Washino et al., 2009). The significance of the findings from
many of these studies has been summarized in a recent review
article (White et al., 2011).
From previous adult exposure studies in rats, it has been
shown that PFOA causes hepatomegaly and a common tumor
triad of hepatocellular adenoma, Leydig cell tumors, and
pancreatic acinar cell tumors (Biegel et al., 2001; Kennedy
et al., 2004). PFOA has also been reported to modulate the
immune system of adult mice (Dewitt et al., 2008; Fairley
et al., 2007; Yang et al., 2002). Exposure to PFOA causes an
array of developmental toxicities in mice. In CD-1 mice,
gestational exposure  10 mg/kg PFOA resulted in increased
prenatal loss and prolonged gestational length in dams,
whereas offspring exhibited reduced birth weight, delayed
eye opening, increased postnatal mortality, delayed sexual
maturation in females, and precocious sexual maturation in
males (Lau et al., 2006). Some of these developmental effects
have been reported at lower doses ( 0.1 mg/kg) in 129S1/
Sv1mj mice (Abbott et al., 2007). Increased body weight (BW)
gain accompanied by elevated serum leptin and insulin was
reported in adult CD-1 mice prenatally exposed to low doses of
PFOA (0.01–1.0 mg/kg BW; Hines et al., 2009). PFOA
exposure may also alter neurodevelopment, as changes in
motor function have been observed in early life (Onishchenko
et al., 2011) and in adulthood (Johansson et al., 2008).
Female rats rapidly eliminate PFOA (t1/2 ¼ 2–4 h vs. 4–6
days in males; Lau et al., 2007). This hyperexcretion leads to
episodic fetal and neonatal body burdens in developmental
exposure studies (Hinderliter et al., 2005). However, gender
differences in elimination of PFOA are not observed in humans
or mice, and thus, mice have been utilized as the more
appropriate rodent model in PFOA studies, particularly in
studies involving developmental or female-specific endpoints.
As it pertains to the mammary gland, both rats and mice are
known to develop in a morphologically similar pattern to the
human breast (reviewed in Fenton, 2006). Due to the
similarities in relative elimination rates of PFOA and mammary
gland development compared with humans, the mouse has
been used in our laboratory as the most appropriate rodent
model.
The mammary gland appears to be a sensitive tissue to
developmental PFOA exposure, although sensitivity may vary
across mouse strains. Prenatal exposure to 5 mg PFOA/kg
severely stunted mammary gland development in female CD-1
offspring (White et al., 2007), and the current lowest observ-
able adverse effect level (LOAEL) for abnormal mammary
gland development in this mouse strain is 3 mg/kg (White
et al., 2009). Recent studies by another laboratory have
demonstrated that peripubertal exposure to 5 mg/kg or higher
PFOA delays mammary gland development in inbred Balb/C
mice and either deters (at 10 mg/kg) or accelerates (at 5 mg/kg)
mammary development in C57Bl/6 mice, depending on dose
(Yang et al., 2009). No significant effects on mammary growth
were detected at 0.1 mg/kg in Balb/C or 1 mg/kg in either strain
(Yang et al., 2009). Thus, even though cross-foster studies
suggest that doses lower than 3 mg/kg may alter mammary
gland development in CD-1 mice (White et al., 2009), studies
in other strains, under different exposure conditions, do not
necessarily support this LOAEL.
Herein, two studies were conducted to further address the
issue of low-dose effects of PFOA in the mammary gland of
CD-1 mice and the internal dosimetry corresponding to these
effects. Specifically, we tested the hypothesis that PFOA
exposures that result in human relevant internal doses are also
associated with perturbed mammary development in mice. In
the first study, with a maximum dose of 3 mg/kg, PFOA was
administered to pregnant mice for the entire gestational period
(GD 1–17), and we determined effects from birth until
adulthood. In a subsequent study, utilizing overlapping and
lower doses, PFOA was administered to pregnant mice for only
the latter portion of gestation (GD 10–17), as this period of
gestation was previously identified as a window of suscepti-
bility for mammary gland developmental abnormalities (White
et al., 2007). In the late-gestation study, we evaluated early life
time points to better assess the internal dosimetry for these
effects in mice. The overarching goal of these two studies was
to establish a LOAEL and a no observable adverse effect level
(NOAEL) for mammary gland effects following prenatal
exposure to PFOA and to determine the corresponding internal
dosimetry associated with these effects.
MATERIALS AND METHODS
Animals
Timed-pregnant CD-1 mice were purchased from Charles River Laborato-
ries (Raleigh, NC). Pregnant dams were housed individually in polypropylene
cages and received chow and tap water ad libitum; both were known to contain
PFOA below the levels of detection. Animal facilities were maintained on
a 12:12 h light-dark cycle at 20C–23C and 40–50% relative humidity.
Chemicals
PFOA (PFOA as its ammonium salt APFO, > 98% pure) was purchased
from Fluka Chemical (Steinhiem, Switzerland), and the PFOA lot number was
identical to previous studies (White et al., 2007, 2009). PFOA dosing solutions
were prepared fresh daily in deionized water, agitated immediately prior to
administration, and were given at a volume of 10-ll solution/g BW.
Experimental Design
Full-gestation exposure study. Fifty-two dams arrived at the animal
facility on GD 0 and were divided into four treatment groups (n ¼ 13 per
treatment). Each group was gavage dosed with deionized water as vehicle
or 0.3, 1.0, or 3.0 mg PFOA/kg BW once daily from GD 1 to 17 (shown
as mg/kg). Upon parturition, the litters were equalized to 10 pups of equal male
and female representation (5:5) when possible. Approximately 15% of the dams
were not pregnant, as expected. The desired number of female offspring was
not always achieved due to inequities in litter sex ratios.
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Late-gestation exposure and early development study. The second study
was performed in two blocks (block 1 ¼ 20 dams, block 2 ¼ 32 dams). Mice
arrived at the animal facility on GD 9 and were divided into four treatment
groups of equal size (block 1 ¼ 5 dams per treatment, block 2 ¼ 8 dams per
treatment). Each group was gavage dosed with deionized water as vehicle or
0.01, 0.1, or 1.0 mg PFOA/kg BW once daily (shown as mg/kg) from GD 10 to
17. Approximately 15% of the dams were not pregnant, again unrelated to
PFOA exposure. To be consistent with previous work (White et al., 2007), on
postnatal day (PND) 1, pups within a treatment group were pooled and
randomly distributed among the dams of their respective treatment group,
resulting in a final litter size of 7–9 pups per dam, with an unequal sex ratio (n
¼ 4–7 females per litter).
Due to the short acclimation periods for both studies (1 day), the dams were
observed by the veterinary staff and study personnel for signs of maternal
stress, such as lack of weight gain or aggressiveness. None were observed.
Necropsy
For the full-gestation study, 6 pups per treatment group (1–2 per dam)
were weighed and then necropsied at PNDs 7, 14, 21, 28, 42, 63, and 84
following decapitation. The trunk blood was collected and centrifuged, and
the serum was collected and stored at 80C. Liver, brain, and one set of
fourth and fifth mammary glands were collected, weighed, and stored at
80C for future RNA analyses. The contralateral fourth and fifth inguinal
mammary glands were removed from female pups for preparation as a whole
mount. Dams were sacrificed on PND 24, and afterward male and female
pups were housed separately. Due to low female pup numbers in the control
group, on PND 63, control females were omitted from the necropsy
schedule.
In the late-gestational study, female pups from at least three litters per
treatment group were weighed, then necropsied on PNDs 1, 4, 7, 14, and 21
following decapitation and the trunk blood was collected, and serum stored as
indicated above. On PND 1 only, serum samples were pooled from several
pups, both male and female, within a litter to achieve sufficient volume for
PFOA analysis. In all further instances, only female endpoints were measured.
Liver and a single set of fourth and fifth inguinal mammary glands were
collected, weighed, and stored at 80C for future RNA and protein analyses.
The contralateral fourth and fifth inguinal mammary gland tissues were
removed to be prepared as whole mounts. Due to lower than expected female
pup numbers, PND 4 measurements were not collected for the 0.1 mg/kg
treatment group.
Mammary Gland Preparations
For whole-mount preparations, mammary tissues were flattened onto glass
slides, fixed in Carnoy’s solution, stained with Carmine alum, and cleared in
xylene as previously described in Fenton et al. (2002). Mammary glands
were evaluated by light microscopy (Leica Z16 APO and Leica DFC295
[Camera], Leica Microsystems, Frankfurt, Germany) and assessed an overall
developmental score based on a 1–4 scale (1 ¼ poor development, 4 ¼ best
development) at each age, similar to methods previously reported (Hilakivi-
Clarke et al., 1997a,b; Welsch et al., 1988). Scores were based on qualitative
and quantitative histological characteristics of each developmental time point,
including, but not limited to, lateral and longitudinal epithelial growth, change
in epithelial growth, appearance of budding from the ductal tree, branching
density, and number of differentiating duct ends (Hilakivi-Clarke et al., 1997a).
Where applicable, at a given time point, mammary glands from both studies
were compared on the microscope to ensure consistency in the scoring scale
between studies.
To better understand the morphological differences between the de-
velopmental scores assessed, in the late-gestational study, several endpoints
were quantitatively measured. Longitudinal growth was defined as the distance
from the nipple end of the primary duct to the most distal terminal duct. Lateral
growth was defined as the distance between the most distal terminal ducts with
the collecting duct as an axis. Terminal end buds (TEBs) were defined as
densely staining, bulbous structures located at the end of mammary ducts that
were at least twice the width of the duct. These endpoints were measured using
the Leica Application Suite (Version 3.5.0, Leica Microsystems). Quantitative
measurements were recorded by one staff member; scoring was performed by
two staff without knowledge of treatment, and the two scores were averaged.
Mean scores for treatment groups were calculated for each time point and
analyzed for statistical significance. Quantitative criteria were analyzed for
statistical significance as well.
Dosimetry
Chromatographic and mass spectrometer conditions. The quantitative
analysis of PFOA was performed using an Agilent 1100 High Performance
Liquid Chromatograph (HPLC; Agilent Technologies, Palo Alto, CA)
interfaced with a Sciex 3000 triple-quadrupole mass spectrometer (HPLC-
MS/MS, Applied Biosystems/MDS Sciex, Foster City, CA).
Blank matrices and quality control. Swiss-Webster mouse serum (with
trace hemolysis) was purchased from Pel-Freeze Biologicals (Rogers, AR) to
prepare blank and spiked quality control (QC) samples and for calibration curve
construction. Liver and brain tissues used to prepare blank and spike QC
samples were obtained from nonpregnant control CD-1 animals that were
sacrificed upon arrival.
A standard curve was prepared by spiking six solutions with serial dilutions
of a 10,000 ng PFOA/ll standard in methanol to obtain final concentrations
across the ranges of PFOA expected in the respective matrices to be analyzed.
For example, for the late-gestation study, serum samples were analyzed with
four separate calibration curves covering 5–50,000 ng PFOA/ml (5–100 ng/ml
for control animals; 5–1000 ng/ml for 0.01 mg/kg animals; 100–5000 ng/ml for
0.1 mg/kg animals; 1000–50,000 ng/ml for 1.0 mg/kg animals). For the full-
gestation study, serum samples were analyzed with one calibration curve
covering 10–40,000 ng PFOA/ml. QC samples were prepared in 25 ll of
Pel-Freeze mouse serum by enrichment with PFOA to obtain multiple
concentrations. For every treatment group, two QC samples were used, one
spiked with a low concentration of PFOA and another spiked with a high
concentration of PFOA relative to the range of the calibration curve.
Calibration curves were generated by plotting the ratio of PFOA peak area to
13C2-PFOA peak area versus concentration and were fitted to a linear regression
equation with 1/x weighting. Batch-specific calibration curves were prepared to
obtain linear curves in the ranges utilized for each treatment group. A minimum
of six standards were used to generate each calibration curve and the
coefficients of determination (r2) values were 0.99 or greater for each analysis.
Matrix-matched standard curves and QC pools were used to minimize potential
errors associated with matrix enhancement or suppression of analyte signal due
to coeluting matrix interferents.
Method accuracy and precision were determined by analyzing the QC
sample repeatedly, using the complete analytical method. Accuracy was
calculated as the percentage of the concentration measured compared with the
theoretical concentration. The precision of the methods was determined by
calculating the average relative SD of the replicate analysis of the QC materials.
Preparation of serum samples. Serum samples were prepared as
previously described in Reiner et al. (2009). Briefly, 25 ll of mouse serum
from the collected samples was transferred into 15 ml polypropylene tubes. An
appropriate amount of internal standard (13C2-PFOA) was added to achieve
the approximate midpoint of the calibration curve of the anticipated sample
range. For example, for serum samples expected to be in the 5–100 ng/ml
range, the standardized amount of labeled PFOA was added to the sample with
1 ml acetonitrile so that it would fall at the midpoint of the calibration curve
(50 ng/ml). Formic acid (0.1M) was added to the serum to denature the proteins
at a volume at least four times the serum volume. The samples were vortexed,
and the cold (20C) acetonitrile internal standard mixture was added to
precipitate proteins in a volume of at least 10 times the formic acid volume
used. The sample was then vortexed and centrifuged at 2000 3 g for 3 min.
A 200-ll aliquot of the acetonitrile supernatant was placed in an HPLC vial
with 2mM ammonium acetate buffer (pH 6.5; 1:1 vol/vol), and the PFOA
concentration was determined using HPLC-MS/MS analysis.
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Preparation of liver and brain samples. One gram of thawed tissue was
placed in 6 ml of distilled water and ground into a homogenized mixture.
Briefly, 50 ll of the liver or brain homogenate was combined with 100 ll of
0.1M formic acid and 1 ml of acetonitrile spiked with 13C2-PFOA. The samples
were vortexed and centrifuged at 3500 3 g for 3 min. A 200-ll aliquot of the
acetonitrile supernatant was placed in an HPLC vial with 2mM ammonium
acetate buffer (pH 6.5) (1:1), and the PFOA concentration was determined
using HPLC-MS/MS analysis.
Sample analysis. Each sample batch of tissue or fluids contained
a maximum of 30 unknowns along with at least 10% QC samples. In
addition, each sample batch included a minimum of six calibration standards,
a matrix blank (containing internal standard and formic acid), and a method
blank (containing internal standard, formic acid, and blank mouse serum,
liver, or brain). Blanks, calibration curve standards, and QCs were all
subjected to the same preparation procedures as the unknown samples. QC
samples were intermixed with unknown samples. If a QC sample exceeded
the range of acceptable variance from that of the theoretical value, the entire
batch was rejected and new aliquots of the samples would be put through the
sample preparation procedure again and rerun. Analytical batches were
considered to be acceptable if the standard curve and QC samples were ± 20%
of the theoretical value. Quantification of some serum samples from the 0.1
mg/kg group from the late-gestation cohort were taken from a batch run in
which the high QC value was just out of the range of the 20% acceptance
criteria compared with the standard curve. However, the unknown sample
values were within the range of the standard curve that was verified by the
low QC value, and thus, these values were deemed acceptable. The limit of
quantitation (LOQ) is defined as the lowest point on the stand curve with back
prediction within ± 30% of the theoretical value. For the serum samples from
the full-gestation study, the LOQ ranged from 10 to 20 ng/ml, whereas
the LOQ for the liver, brain, and late-gestation serum samples were 35 ng/g,
35 ng/g, and 5 ng/ml, respectively. Analytical values below the LOQ were
reported as the calculated value of LOQ/O2 for purposes of statistical
comparisons.
Statistical Analysis
Dams, or litter, were utilized as the unit of measure for statistical analysis
throughout both studies. Thus, when more than one pup was necropsied from
one dam, the values were averaged and the mean was used for statistical
analysis. Data were evaluated by age and treatment using general linear model
ANOVA in SAS 9.1 (SAS Institute, Inc., Cary, NC). In the late-gestation study,
data were evaluated for block and treatment effects by ANOVA mixed model
analysis. Due to slight variance in litter sizes, litter and litter 3 treatment effects
were evaluated and data were assessed for normal distribution. In cases where
a litter 3 treatment effect existed, data within a treatment group were evaluated
for significant outliers calculated by Grubbs’ test utilizing GraphPad’s
QuickCalc outlier online calculator (2005) and were removed from analysis
if detected. For all measurements, data are reported as the mean ± SEM.
Differences between PFOA-treated groups and controls were determined using
Dunnett’s t-tests. Differences within PFOA-treated groups over time were
determined utilizing Tukey’s t-tests. Differences between the 1.0 mg/kg full-
gestation and late-gestation groups were determined using Student’s t-tests.
In the full-gestation study, due to the lack of female controls at PND 63, no
statistical differences were determined for that time point. Due to low male
numbers throughout the study, the male data were considered incomplete and
were statistically analyzed with low power. They are briefly discussed herein,
and the data are provided in the Supplementary tables.
Net pup weights were calculated to determine if PFOA-induced increases in
liver weight disguised a BW effect. They were calculated by subtracting liver
weight from BW for an individual. Means were then calculated for each dose
group. Relative tissue weights were calculated by dividing the absolute tissue
weight by the individual BW. For relative tissue weights and dosimetry data,
the values were log transformed prior to statistical analysis. For mammary
gland endpoints in the late-gestation study, change in epithelial growth was
calculated as the difference between the measured length at a given time point
from the respective treatment mean values at PND 1. A value of p  0.05 was
used as the limit to determine statistical significance.
RESULTS
Full-Gestation PFOA Exposure Study
Body weights. A comparison of female and male offspring
BWs over time are shown in Supplementary tables 1 and 2.
Also shown are net pup weights, following subtraction of liver
weights. PFOA (0.1–3.0 mg/kg) did not affect the absolute or
net weights of either female or male offspring (Supplementary
tables 1 and 2).
Liver weights. Gestational exposure to low doses of PFOA
elevated the absolute and relative liver weights in both females
and males compared with respective controls (Supplementary
tables 1 and 2). Importantly, on PND 7, prenatal PFOA
exposure elevated relative liver weights in the 0.3 mg/kg
treatment group in both females and males, a dose that is lower
than the previously reported LOAEL in CD-1 mice (Lau et al.,
2006; Wolf, et al., 2008). This effect had dissipated after PND
7. In the 1.0 mg/kg group, the relative liver weights remained
elevated in females on PNDs 7 and 14 (p < 0.05) and were also
elevated on PNDs 7 and 42 in the males (p ¼ 0.02). In the 3.0
mg/kg group, the relative liver weights remained elevated from
PNDs 7 to 28 in the females (p  0.05) and similarly elevated
at PNDs 7, 14, 21, and 42 in the males (p < 0.001). These
elevated liver weights are indicative of hepatomegaly, a
common effect of PFOA exposure. The extent of liver weight
elevation illustrates the dose-dependent effect of PFOA for
this endpoint.
Brain weights. Gestational PFOA exposure decreased
absolute brain weights only at PND 63 in the males of the
two highest treatment groups (1.0 and 3.0 mg/kg; p < 0.05,
Supplementary table 2); yet, there were no statistical differ-
ences in the PFOA-treated females at any time point (Sup-
plementary table 1). Also, there were no differences in relative
brain weights of either gender. These data suggest that, across
dose and time, PFOA exposure has little (male) or no effect
(female) on brain weight.
Mammary glands. Mammary glands from PFOA-treated
groups exhibited histological characteristics of delayed epithe-
lial growth, similar to those documented in rats neonatally
exposed to endocrine-disrupting compounds (Brown et al.,
1998; Fenton, 2006; Fenton et al., 2002) and had lower
developmental scores compared with controls (Supplementary
table 3). Even the lowest treatment group (0.3 mg/kg) had
developmental scores that were statistically lower compared
with controls at numerous time points (PNDs 14, 21, 42, and
84). Representative mammary gland whole mounts from the
control, 0.3 mg/kg, and 1.0 mg/kg treatment groups at PNDs
21 and 84 are shown in Figure 1. In normal mouse mammary
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gland development, from PNDs 1 to 14, the primary duct
extends from the nipple area toward the lymph node, branching
to fill the mammary fat pad. After PND 14, the mouse
mammary gland forms TEBs, which are the precursors of
future branching (Watson and Khaled, 2008). As the mammary
gland grows, it continues to branch and form additional TEBs
until the entire fat pad has been filled. The branches extend
toward the ends of the fat pad, and the TEBs disappear as they
differentiate into terminal structures around PND 63 (Watson
and Khaled, 2008), so that in the adult mouse at PND 84, there
are no TEBs. The presence of numerous TEBs at PNDs 63 and
84 in the offspring of the PFOA-treated animals in this study
are indicative of substantial mammary gland developmental
delays. In the absence of control glands at PND 63, we
compared our PFOA-treated glands to historical controls from
previous studies (White et al., 2009); thus, these data may
necessitate repeating. Nevertheless, epithelial branching in
treated glands did not fill the mammary fat pad as completely
as the controls, which was highly evident at PND 84 (Fig. 1).
Serum PFOA concentrations. Serum PFOA concentration
data from female offspring are summarized in Figure 2 and
detailed in the Supplementary table 4, and male offspring data
are detailed in Supplementary table 5. As would be expected,
the highest concentrations of PFOA were found in the serum of
pups in the 3.0 mg/kg group. In the females of the 1.0 and 3.0
mg/kg treatment groups, the mean serum PFOA concentrations
peaked at PND 14 and then gradually declined through the
remainder of the study. However, in the 0.3 mg/kg group, the
highest serum concentrations occurred at PND 7 (Fig. 2,
Supplementary table 4). The serum concentrations of all
PFOA-treated groups were statistically elevated from PNDs 7
until 42 and in the two highest exposure groups (1.0 and 3.0
mg/kg) until PND 84 in females.
Unlike the adult, in the developing animal, the BW and
blood volumes increase rapidly from birth to weaning. The
FIG. 1. Female offspring mammary gland whole mounts in the full-gestation study. Control glands from (A) PNDs 21 and (D) 84; 0.3 mg/kg glands from
(B) PNDs 21 and (E) 84; 1.0 mg/kg glands from (C) PNDs 21 and (F) 84. Glands pictured are representative of mean score for each treatment group; n ¼ 3–5 (PND
21) and 2–4 (PND 84). At PND 21 (top panel), PFOA-exposed glands (B and C) are smaller in overall size, with poor branching patterns and fewer visible TEBs
when compared with the control gland (A). At PND 84 (bottom panel), the PFOA-exposed glands (E and F) have poor branching patterns, poor differentiation, and
several TEBs. All PFOA-treated mammary glands received significantly lower developmental scores compared with controls at both time points (p  0.01).
FIG. 2. Serum PFOA concentration in female offspring following the
full-gestation exposure. Data presented as the mean ± SEM. Litter n ¼ 2–5
(PND 7), 4–6 (PND 14), 3–6 (PND 21), 3–6 (PND 28), 4–6 (PND 42), 2–5
(PND 63), and 1–5 (PND 84). *Significant treatment effect compared with
controls (p  0.01).
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increasing blood volumes and BWs of the offspring were taken
into account to estimate the total blood burdens of PFOA in the
pups from this study to understand when the body burden
peaks. We developed a formula to calculate the estimated total
amount of PFOA in the blood per pup based on weight and
serum PFOA concentrations. This calculation is based on the
assumption that there is approximately 58.5 ml of blood/kg
BW in the mouse and that 55% of the whole blood is serum
(Hoff, 2000) resulting in the equation: blood burden ¼ [BW
(58.5 ml/kg/1000) 3 serum concentration 3 55%]. The total
blood burdens were calculated using the analytical values from
the HPLC-MS/MS, regardless if values were below the LOQ
for each individual sample. Developmental effects are heavily
influenced by timing of exposure, in relation to organogenesis,
as well as dose. Thus, comparisons of total blood burdens over
time may provide insight into the timing or extent of adverse
effects of toxicant exposure, particularly in the developing
animal. In addition, blood burdens may be more useful for
interspecies comparisons ‘‘(o)wing to the gender and species
difference in elimination’’ of PFOA and other perfluoroalkyl
acids (Lau et al., 2007). Evaluation of total blood content of
PFOA over time resulted in an inverted U-shaped curve in
females (Fig. 3; Supplementary table 4), with a peak at PND 14
for all doses, which happen to occur after lactation peaks and
just before pups begin to rely on solid food and water for their
sustenance. As with the serum concentrations, all treatment
groups had calculated total blood burdens of PFOA that were
statistically greater than controls from PNDs 7 to 42.
Liver PFOA concentrations. It should be noted that the
livers were not perfused before analysis; therefore, residual
amounts of blood were potentially analyzed with these tissues.
The concentration of PFOA was greater in liver samples of
females in all treated groups compared with controls from
PNDs 7 to 42 (Supplementary table 4). The highest liver
concentrations of PFOA were found at PND 7, and unlike
serum concentrations, the liver concentrations decreased or
remained constant from PND 7 to PND 14 (Figure 2;
Supplementary table 4). At the two latest time points evaluated,
the mean PFOA concentrations in the liver were higher
compared with concentrations in the serum (with exception of
1.0 mg/kg at 84 days). This trend has been observed in other
studies (Kudo et al., 2007) and suggests that the liver may be
a more sensitive biomarker than serum for long-term PFOA
exposure estimates.
Brain PFOA concentrations. As with the livers, the brain
samples were not perfused before analysis of PFOA content.
PFOA was present in the brain on PND 7 in all treatment
groups but at substantially (10- to 30-fold) lower levels than in
serum or liver. Judging from these diminishing trends, our
data demonstrated that, relative to serum and liver, PFOA is
more readily eliminated from the brain. Brain PFOA
concentrations in the females remained statistically elevated
compared with controls on PND 7 and PND 14 in the 0.3 and
1.0 mg/kg treatment group and from PND 7 until PND 28 in
the 3.0 mg/kg group (Supplementary table 4).
Late-Gestation PFOA Exposure Study
Body weights. No significant differences in BW or net
BWs were observed at any time point in the PFOA-exposed
groups when compared with controls (Supplementary table 6).
No differences in BW were expected at these exposure levels
based on previous data from Lau et al. (2006).
Liver weights. Absolute liver weights in the highest
treatment group (1.0 mg/kg) were significantly increased
compared with controls from PND 4 through PND 7 (p <
0.05, Supplementary table 6). The relative liver weights were
also significantly increased in this treatment group from PND 4
through 14 (p < 0.05, Supplementary table 6). There was no
effect at the 0.1 mg/kg dose or lower. The effects in the 1.0 mg/
kg group were independent of BW and demonstrate that liver
weight effects are dose and exposure length dependent; the
LOAEL for hepatomegaly from late-gestation exposure was
1.0 mg PFOA/kg, whereas 0.3 mg PFOA/kg was adequate to
induce significant hepatomegaly in the full-gestation exposure.
Mammary glands. Upon visual observation, mammary
glands of PFOA-exposed mice displayed aberrant morphology
and thus were assessed lower developmental scores compared
with controls (Fig. 4). It should be noted that statistical
differences found in a single quantitative endpoint did not
necessarily determine aberrant development; rather, all quan-
titative and qualitative measurements were collectively utilized
to determine overall developmental mammary gland scores. At
PND 14, the longitudinal epithelial growth of the mammary
glands from the 0.1 and 1.0 mg/kg groups was reduced
compared with controls by 14.4% (p ¼ 0.04) and 37.3% (p ¼
0.01), respectively, and the change in longitudinal growth from
FIG. 3. Calculated PFOA blood burdens in female offspring following
full-gestation exposure. Data presented as the mean ± SEM. Calculated blood
burden is determined by the equation [BW (58.5 ml/kg/1000) 3 serum 3 55%]
for litters, and mean values are presented for each treatment group. Litter n ¼
2–5 (PND 7), 4–6 (PND 14), 3–6 (PND 21), 3–6 (PND 28), 4–6 (PND 42), 2–3
(PND 63), and 1–5 (PND 84). *Significant treatment effect compared with
controls (p  0.01).
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PNDs 1 to 14 was reduced by 27.4% (p ¼ 0.005) and 56.5%
(p ¼ 0.002), respectively. Developmental delays were most
evident at PND 21, and all treated groups exhibited statistically
lower developmental scores compared with controls (p < 0.02;
Table 1). Developmental scores and quantitative endpoints at
PND 21 are presented in Table 1; mammary gland whole
mounts from PND 21 are presented in Figure 4. At PND 21,
the pups in the highest dose group (1.0 mg/kg) displayed
the most impaired mammary gland growth, with low mammary
gland scores, poor longitudinal epithelial growth, and fewer
TEBs (p < 0.05; Table 1). Taking all developmental
criteria into consideration, the lowest dose at which mammary
gland developmental abnormalities were visible was 0.01 mg
PFOA/kg.
Serum PFOA concentrations. Serum PFOA concentrations
in all exposed litters were statistically higher than controls at all
time points and in a dose-dependent manner (Fig. 5). The
highest serum concentrations were found at PND 1 and
gradually declined until the end of the study. Even at the lowest
dose (0.01 mg/kg), the mean serum PFOA concentration was
not reduced to the levels of controls before the conclusion of
the study at PND 21.
As with the full-gestational cohort, we also assessed the total
PFOA blood content per pup as an indicator of body burden. In
all treatment groups, the total blood PFOA content did not
change from PND 7 to PND 14 and then declined substantially
thereafter (Fig. 6; Supplementary table 7). PFOA blood
burdens among the treated groups were statistically elevated
at all time points measured (p < 0.05).
To better understand the developmental toxicity of PFOA,
we compared the dosimetry data from the 1.0 mg/kg females of
the full-gestation study to those of the late-gestation study.
These comparisons are highlighted in Figure 7 and also in
Supplementary tables 4 and 7 and revealed unexpected
similarities in PFOA serum dosimetry. However, it should be
noted that slight differences in timing of necropsies or litter size
may have some influence on the serum concentrations of
offspring, and thus, these comparisons have been cautiously
interpreted. There were no differences detected in the serum or
calculated blood burdens at PND 7 of the two study groups,
although the pups in the full-gestation study received 10
additional days of exposure. Large differences were expected at
this point. The full-gestation 1.0 mg/kg females had mean
serum and calculated blood burdens that were nearly twofold
greater than those of the late-gestation study at PND 14 and
PND 21, as expected.
DISCUSSION
The present studies demonstrate that exposure to PFOA
throughout gestation (GD 1–17) or during the latter half of
gestation (GD 10–17) at doses 10- to 30-fold lower than
previously investigated are sufficient to produce abnormal
mammary gland development in CD-1 mice. In both studies,
FIG. 4. Female offspring mammary gland whole mounts at PND 21 in the late-gestation study from (A) controls, (B) 0.01 mg/kg, (C) 0.1 mg/kg, and (D) 1.0
mg/kg. Glands pictured are representative of the mean score for each treatment group; n ¼ 3–5. PFOA-exposed glands were smaller in size, displayed poor
branching patterns, and had fewer TEBs relative to controls. All PFOA-treated mammary glands received significantly lower developmental scores compared with
controls (p < 0.05).
TABLE 1













Control (n) 3.3 ± 0.3 (5) 4321 ± 306 (5) 5941 ± 280 (5) 3394 ± 306 (5) 4358 ± 280 (5) 40 ± 4 (5) 81 ± 12 (5)
0.01 mg/kg (n) 2.2 ± 0.2* (4) 3803 ± 386 (4) 5420 ± 326 (4) 3087 ± 386 (4) 3899 ± 326 (4) 33 ± 4 (4) 61 ± 8 (4)
0.1 mg/kg (n) 1.8 ± 0.3** (3) 3615 ± 320 (3) 4822 ± 672 (3) 2370 ± 320 (3) 3035 ± 672 (3) 24 ± 4* (3) 58 ± 4 (3)
1.0 mg/kg (n) 1.6 ± 0.1*** (5) 2775 ± 285** (5) 4822 ± 313 (5) 1553 ± 301** (5) 3380 ± 313 (5) 15 ± 2***(5) 47 ± 11 (5)
Note. Mammary gland measurements from late-gestation female offspring at PND 21. Data presented as the mean ± SEM.
Significant effects compared with controls, *p < 0.05, **p < 0.01, ***p < 0.001.
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low doses of PFOA elevated relative liver weights and stunted
mammary gland development. Full-gestational exposure to 
0.3 mg/kg PFOA resulted in reduced mammary gland
developmental scores compared with controls at perinatal
(PNDs 14 and 21), peripubertal (PND 42), and adult (PND 84)
time points. Moreover, exposure to 30-fold lower doses of
PFOA (0.01 mg/kg) during GD 10–17 suppressed mammary
gland development as well. These data suggest that prenatal
exposure to PFOA may alter mammary gland development in
CD-1 mice at doses lower than investigated here. Additionally,
effects on mammary tissue were observed at doses of PFOA
lower than those required to exert an effect on the liver and the
mammary effects persisted longer. These findings implied that
in CD-1 mice, the mammary gland was more sensitive to
prenatal PFOA exposure than was the liver.
In a previous study by Yang et al. (2009), peripubertal
exposures to PFOA in Balb/C and C57Bl/6 mice resulted in
mammary gland growth effects at doses  5 mg/kg but not at
 1 mg/kg, even though elevated liver weights were observed at
1 mg/kg. Thus, the mammary gland effects presented from our
studies appear to be the result of an increased sensitivity in the
CD-1 mouse strain. We postulate that intraspecies differences in
effects are more likely due to the timing of exposure, as there are
strain differences in timing of puberty (Nelson et al., 1990); yet,
mammary gland morphology remains fairly consistent during
stages of development (i.e., puberty and pregnancy). Further
research is needed to determine if the sensitivity is attributed to
timing of exposure or the mouse strain utilized or if there are
other novel mechanisms underlying this apparent sensitivity in
CD-1 mice.
The developmental scoring method utilized in these studies,
which incorporated both qualitative and quantitative endpoints,
accurately predicted the long-term mammary gland develop-
mental delays seen in PND 84 full-gestation–treated animals.
Following full-gestational PFOA exposure, several TEBs
remained in PFOA-treated mammary glands at PND 84. Other
studies have shown that the extended presence of TEBs, in
general, can lead to long-term adverse effects on the gland,
including a higher risk for mammary tumor formation
following exposure to carcinogens (Russo and Russo, 1978)
and altered lactation (Rayner et al., 2005). Although it is
unclear whether there are lasting adult effects on the mammary
gland due to late-gestation exposure, evaluation of mammary
FIG. 6. Calculated PFOA blood burdens in offspring from the late-
gestation study. Data presented as the mean ± SEM. Calculated blood burden is
determined by the equation [BW (58.5 ml/kg/1000) 3 serum 3 55%] for
litters/individual pups, and mean values are presented for each treatment group.
Litter n ¼ 2–7 (PND 1), 2 (PND 4), 5–11 (PND 7), 7–11 (PND 14), and 7–11
(PND 21). *Significant treatment effect compared with controls (p < 0.001).
FIG. 7. Comparison of 1.0 mg/kg treatment group dosimetry in full- and
late-gestation study. (A) Serum PFOA concentrations and (B) calculated PFOA
blood burdens of female offspring from the 1.0 mg/kg treatment group from the
full- and late-gestation studies. Data presented as the mean ± SEM. Litter n ¼ 7
(PND 1), 5–11 (PND 7), 6–11 (PND 14), and 5–11 (PND 21). *Significant
differences by ANOVA (p < 0.001).
FIG. 5. Serum PFOA concentration of female offspring from the late-
gestation study. Data presented as the mean ± SEM. Litter n ¼ 2–7 (PND 1), 2
(PND 4), 5–11 (PND 7), 7–11 (PND 14), and 7–11 (PND 21). *Significant
treatment effect compared with controls (p < 0.001).
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tissues indicated that prenatal exposure to doses as low as 0.01
mg PFOA/kg can also lead to developmental delays. Thus, we
did not identify an NOAEL for PFOA-induced mammary
gland developmental effects in CD-1 mice.
In the full-gestational study, relative liver weights were
elevated in the 0.3 mg/kg group, which is lower than the
previously reported liver LOAEL of 1.0 mg/kg in this mouse
strain (1.0 mg/kg was the lowest dose utilized; Lau et al., 2006;
Wolf et al., 2008). Another recent study found that prenatal
exposure to 0.3 mg/kg of PFOA elevated absolute liver weights
independent of BW differences (Onishchenko et al., 2011).
Importantly, in the late-gestation study, we used exposure
periods that were half the length previously used; yet, this
study produced comparable effects on liver weights at the same
doses reported previously (Lau et al., 2006). This warrants
strength to the supposition that the LOAEL for PFOA-induced
liver hepatomegaly in CD-1 mice is lower than 1.0 mg/kg and
that the NOAEL is approximately 0.1 mg/kg.
PFOA did not appear to affect brain weights in our studies.
However, the presence of PFOA in the tissue warrants further
investigation, as it may impart other effects to the brain.
A recent study (Johansson et al., 2008) showed that low-level
developmental exposure to PFOA produced behavioral effects
in mice that extended into adulthood. Onishchenko et al.
(2011) reported that prenatal exposure to 0.3 mg/kg affected
activity levels in mice independent of brain weight changes.
The presence of PFOA in the neonatal brain, coupled with its
absence after four weeks of age, suggests that PFOA passes
through the fetal mouse blood-brain barrier but is not able to
pass through the fully functional barrier that is normally
formed by the time of birth (Bauer et al., 1993).
Theoretically, animals dosed for longer periods are expected
to exhibit higher serum concentrations than those exposed for
shorter periods. However, as seen in Figure 7, there are
similarities in the serum PFOA concentration of 1.0 mg/kg
females from the full-gestation study compared with those of
the late-gestation study at PND 7. Other studies have found that
there are comparable serum concentrations in adult CD-1 mice
following differing lengths of exposure (Lau et al., 2006). It is
postulated that these similarities in PFOA serum concentrations
are attributable to differences in clearance rates relative to
exposure length. In a study by Lou et al. (2009), with repeated
low doses of PFOA, net urinary elimination rates of PFOA
were found to be high, potentially due to saturation of renal
resorption. However, in the same study, urinary elimination
rates were found to be low when resorption saturation was not
reached. Thus, it is speculated that the longer exposure
parameters for the full-gestation study offspring resulted in
higher urinary elimination rates and consequently higher blood
clearance rates, which may have reduced the serum PFOA
concentration to comparable levels of the offspring exposed
during late gestation. Additionally, it is important to consider
the functional capacity of the developing urinary system in
pups at this age relative to their ability to eliminate toxicants.
A temporal comparison revealed that the mean serum PFOA
concentration and calculated blood burden of the 1.0 mg/kg
group female offspring were greatest at PND 14 in the full-
gestation study, whereas in the 1.0 mg/kg female offspring of
the late-gestation study, the mean serum concentration was
greatest at PND 1 and the calculated PFOA blood burden was
greatest from PNDs 7 to 14 (Fig. 7, Supplementary tables 4
and 7). A similar trend to that observed in the late-gestation
females was also seen in mice given a single prenatal dose of
PFOA with analytically measured, not calculated, body
burdens (Fenton et al., 2009).
After parturition, offspring of PFOA-treated lactating dams
experience extended exposure via milk consumption (Fenton
et al., 2009). In addition to the PFOA that is transported into
milk from the blood supply, the grooming habits of rodents
further contribute to milk-borne exposure; PFOA present in
urine of PNDs 1–10 offspring is consumed by dams and
subsequently recirculated back into the maternal system
(Rodriguez et al., 2009). Due to the relationship between
maternal grooming habits and pup exposure, pup urinary
excretion rates can also influence the availability of PFOA for
recycling by the dam. Therefore, higher urinary excretion rates
in pups may indeed account for greater serum PFOA
concentrations and blood burdens at the second week of age
in those exposed throughout gestation compared with those
exposed from GD 10 to 17.
Importantly, serum PFOA concentrations found in the 0.01
mg/kg group are lower than those measured in young children
living in areas highly contaminated with PFOA, such as the Ohio
River Valley in West Virginia (Emmett et al., 2006). Emmett
et al. (2006) reported that the 2004 mean serum PFOA
concentrations were near 600 ng/ml in children aged 2–5 years
from the Ohio River Valley area. Approximately 2 years later,
and after some exposure intervention, Frisbee et al. (2009)
reported mean serum concentration of 77.6 and 59.9 ng/ml in
children from the C8 Health Project of age< 12 and 12–19 years,
respectively. The late-gestation study conducted here observed
mice only until weaning, which would be equivalent to 2–3 years
of age in humans. Due to the elimination rates of PFOA in female
mice (t1/2 ~16 days, Lou et al., 2009), it can be assumed that
serum PFOA levels of pups in the 0.1 mg/kg treatment group
would have decreased after PND 21 to levels approaching, if not
lower, than those reported in children by Frisbee et al. (2009).
Importantly, from the full-gestation study mammary glands, we
observed that the developmental effects were not transient and in
fact were apparent at adulthood, although PFOA exposure had
ceased 12 weeks earlier. These findings are of great concern
considering that children are likely to be exposed to PFOA
prenatally, as well as throughout life. Therefore, it is important to
determine the human relevance of the observed endpoints in
relation to internal dosimetry to establish a benchmark dose for
the PFOA mammary gland effects.
It is also critical to establish a mode of action (MOA) for the
developmental mammary gland growth effects following
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PFOA exposure to determine whether this MOA is biologically
relevant to humans. The liver toxicity and general develop-
mental effects of PFOA are believed to be mediated by
activation of peroxisome proliferator–activated receptor-alpha
(PPAR-a) (Abbott et al., 2007; Rosen et al., 2009; Wolf et al.,
2008); yet, there are data to suggest that PFOA-induced
mammary gland effects are mediated by other pathways (Zhao
et al., 2010). Previous studies using PPAR-a knockout (KO)
mice reported normal lactation after exposure to PFOA (Zhao
et al., 2010). Changes in serum progesterone reported in the
study of Zhao et al. (2010) suggest that stimulatory, and
potentially inhibitory, mammary gland effects may be mediated
through endocrine disruption. PFOA may indirectly affect
branching morphogenesis through modulation of progesterone
synthesis (Zhao et al., 2010), and other endocrine-disrupting
effects of PFOA have been reported (White et al., 2011). In the
future, we plan to further compare mammary gland de-
velopmental effects in PPAR-a wild-type and KO mice after
prenatal PFOA exposure to determine whether PPAR-a
activation is involved in this outcome.
In summary, an NOAEL was not achieved in either study for
PFOA-induced mammary gland effects in CD-1 mice, as
altered mammary gland development was observed in off-
spring of dams treated with the lowest PFOA dose utilized in
each study. As these are the lowest doses of PFOA tested in
CD-1 mice thus far, additional studies are necessary to
determine an NOAEL, as well as to establish the human
relevance of PFOA-induced mammary gland effects.
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